Published in Proc Natl Acad Sci U S A on October 18, 2010
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol (2014) 2.34
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
The human antibody response to dengue virus infection. Viruses (2011) 1.79
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature (2015) 1.72
Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol (2013) 1.68
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis (2012) 1.39
A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med (2014) 1.37
Structural Basis of Zika Virus-Specific Antibody Protection. Cell (2016) 1.27
Crystal structure of the Japanese encephalitis virus envelope protein. J Virol (2011) 1.26
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog (2015) 1.23
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis (2012) 1.22
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun (2015) 1.18
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 1.12
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife (2013) 1.10
Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol (2014) 1.00
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog (2013) 0.94
West Nile virus: A re-emerging pathogen revisited. World J Virol (2012) 0.94
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Vaccines in development against West Nile virus. Viruses (2013) 0.90
Zika Virus: Immunity and Vaccine Development. Cell (2016) 0.89
A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus. J Virol (2012) 0.89
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies. Virol J (2013) 0.83
A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci (2014) 0.83
Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe. PLoS One (2013) 0.82
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int (2013) 0.80
Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Rep (2015) 0.80
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog (2017) 0.79
A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat Commun (2017) 0.79
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
B cell response and mechanisms of antibody protection to West Nile virus. Viruses (2014) 0.78
Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol (2014) 0.77
Physico-chemical requirements and kinetics of membrane fusion of flavivirus-like particles. J Gen Virol (2015) 0.77
Identification of conserved motifs in the West Nile virus envelope essential for particle secretion. BMC Microbiol (2013) 0.76
Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses. Biophys J (2016) 0.75
Dengue virus: Bumps in the road to therapeutic antibodies. Nature (2015) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res (2016) 0.75
Human antibodies stop dengue virus by jamming its mechanics. Proc Natl Acad Sci U S A (2014) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
The interpretation of protein structures: estimation of static accessibility. J Mol Biol (1971) 40.24
EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J (2004) 4.05
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell (2001) 3.23
Combining electron microscopic with x-ray crystallographic structures. J Struct Biol (2001) 3.07
Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol (2002) 2.66
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
AUTO3DEM--an automated and high throughput program for image reconstruction of icosahedral particles. J Struct Biol (2006) 2.35
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol (2006) 2.20
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Antigenic structure of flavivirus proteins. Adv Virus Res (2003) 2.15
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Antibody elbow angles are influenced by their light chain class. J Mol Biol (2006) 1.96
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol (2005) 1.86
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
West Nile virus in the Americas. Med Clin North Am (2008) 1.78
Structure of immature West Nile virus. J Virol (2007) 1.77
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature (1992) 1.57
Flavivirus structure and membrane fusion. Adv Virus Res (2003) 1.39
Capturing a flavivirus pre-fusion intermediate. PLoS Pathog (2009) 1.24
Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem (2005) 1.23
Characterization of the functional requirements of West Nile virus membrane fusion. J Gen Virol (2009) 1.17
The host immunologic response to West Nile encephalitis virus. Front Biosci (Landmark Ed) (2009) 1.13
Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods (2000) 1.13
Intramolecular signaling upon complexation. FASEB J (1995) 0.94
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol (2003) 4.48
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Outcome of the first electron microscopy validation task force meeting. Structure (2012) 4.35
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol (2003) 4.11
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
Structure of West Nile virus. Science (2003) 3.48
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Structure of the cell-puncturing device of bacteriophage T4. Nature (2002) 3.32
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Three-dimensional rearrangement of proteins in the tail of bacteriophage T4 on infection of its host. Cell (2004) 3.31
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol (2003) 3.29
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
The structure of the phage T4 DNA packaging motor suggests a mechanism dependent on electrostatic forces. Cell (2008) 3.07
The structure and evolution of the major capsid protein of a large, lipid-containing DNA virus. Proc Natl Acad Sci U S A (2002) 3.07
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 2.97
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 2.84
The tail structure of bacteriophage T4 and its mechanism of contraction. Nat Struct Mol Biol (2005) 2.82
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
Conservation of the capsid structure in tailed dsDNA bacteriophages: the pseudoatomic structure of phi29. Mol Cell (2005) 2.80
Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol (2008) 2.66
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
Structural and functional similarities between the capsid proteins of bacteriophages T4 and HK97 point to a common ancestry. Proc Natl Acad Sci U S A (2005) 2.53
Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. Proc Natl Acad Sci U S A (2009) 2.52
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol (2008) 2.35
Structural changes of envelope proteins during alphavirus fusion. Nature (2010) 2.32
Outcome of a workshop on archiving structural models of biological macromolecules. Structure (2006) 2.32
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A (2004) 2.24
Picornavirus-receptor interactions. Trends Microbiol (2002) 2.23
Reovirus polymerase lambda 3 localized by cryo-electron microscopy of virions at a resolution of 7.6 A. Nat Struct Biol (2003) 2.21
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18